Clinical Trials Browser

OTHER × Neoadjuvant Immunotherapy × Immunotherapy × Clear all

NCT07231575 2025-11-18

Neoadjuvant SBRT and Tislelizumab (Immunotherapy) Plus Anlotinib for Resectable EGFR Wild-type NSCLC

Phase 2 Not yet recruiting

Neoadjuvant Immunotherapy